Trametinib dimethylsulfoxide is the main compound of Mekinist's drug, used to treat melanoma, a type of skin cancer, produced by GlaxoSmithKline.
This medication is found in tablet form, with a concentration of 0.5 mg, 1 mg and 2 mg. Mekinist is a prescription drug used to treat people with this type of skin cancer.
Indications
For the treatment of patients with metastatic melanoma who can not be operated on, either with BRAF V600E or V600K, mutations detected by an FDA approved test.
Side effects
In 10% of patients treated Mekinist, some symptoms such as: rash, dermatitis, dry skin, pruritus, paronychia, diarrhea, stomatitis, abdominal pain, lymphedema, hypertension, hemorrhage, can compromise fertility, among others. Mekinist can cause cardiomyopathy, severe visual disturbances that can lead to blindness, interstitial lung disease (or pneumonitis), and hypertension. Patients are advised to notify their physician immediately in case of any signs or symptoms.
How to use
The recommended dose is 2 mg orally once daily until disease progression or unacceptable toxicity. Take at least 1 hour before or 2 hours after a meal. Do not take a dose within 12 hours of the next dose.
Contraindication
Infants, people with reproductive potential. Mekinist should not be used to treat people who have received a BRAF inhibitor for the treatment of melanoma.
